Welcome to Viatris Mylan is now part of Viatris, a new global healthcare company committed to empowering people to live healthier at every stage of life. We encourage you to learn more about our commitment to increasing access to quality medicines for patients when and where they need them. ...
See FDA’s guidance documentM7 (R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Riskfor approaches to consider where appropriate regarding the presence of mutagenic impurities, athttps:...
by Mylan Pharmaceuticals Inc., and the company is shipping product immediately. Mylan CEO Heather Bresch commented: "The approval and immediate launch of our Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg, represents an exciting advance for the women's health care fra...
and Andrew Pollack covers pharmaceuticals for The New York Times. Gentlemen, welcome. Andrew Pollack, I want to start with you and ask you to explain just basically what's the difference here? What's the big deal between a generic EpiPen and the kind that this company has been producing ...
Mylan is the latest manufacturer to get caught up in growing public criticism of drug price hikes, following Valeant andTuring Pharmaceuticals.
standing at 27% and 44%, respectively. Notably, since January 8, 2014, when my appointment as CEO was announced following which we began executing our current strategy, Teva’s TSR was 53%, significantly outperforming the S&P 500 Index’s 18% and S&P 500 – Pharmaceuticals Index’s 29% re...
See FDA’s guidance document M7 (R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk for approaches to consider where appropriate regarding the presence of mutagenic impurities, at https...